DRMA dermatarx.com: Company Value to Revenue

Public company logo of Dermata Therapeutics Inc (DRMA)

Dermata Therapeutics focuses on developing the innovative drug DMT310 to treat rosacea and acne. The shift in the EV/Sales ratio demonstrates the impact of clinical successes and patent protection on the share price, while -34285.71 reflects the latest level of the metric. The absence of sales makes cost growth linear, and the production outsourcing model provides the team with flexibility without requiring capital expenditures.

DRMA Dermata Therapeutics Inc Company Value to Revenue (11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for Dermata (DRMA)

- current price and projected stock value:
- company stock capitalization data:
Fundamental valuation:Dermata Therapeutics (DRMA)
Mass-produced product of Dermata Therapeutics Inc

This indicator determines business value through the ratio of enterprise value to revenue, excluding the impact of debt load to identify actual market overpayment. By analyzing the EV-to-annual-revenue multiple, an investor separates speculative noise from the fundamental value of Dermata Therapeutics (DRMA), whose innovative microneedle platforms enable the scaling of sales within the oversaturated acne and rosacea treatment segment.